AMP-Activated Protein Kinase (AMPK)-Dependent Regulation of Renal Transport

Philipp Glosse 1 and Michael Föller 2,*

1 Institute of Agricultural and Nutritional Sciences, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany; philipp.glosse@landw.uni-halle.de
2 Institute of Physiology, University of Hohenheim, D-70599 Stuttgart, Germany
* Correspondence: michael.foeller@uni-hohenheim.de; Tel.: +49-711-459-24566

Received: 26 September 2018; Accepted: 30 October 2018; Published: 6 November 2018

Abstract: AMP-activated kinase (AMPK) is a serine/threonine kinase that is expressed in most cells and activated by a high cellular AMP/ATP ratio (indicating energy deficiency) or by Ca^{2+}. In general, AMPK turns on energy-generating pathways (e.g., glucose uptake, glycolysis, fatty acid oxidation) and stops energy-consuming processes (e.g., lipogenesis, glycogenesis), thereby helping cells survive low energy states. The functional element of the kidney, the nephron, consists of the glomerulus, where the primary urine is filtered, and the proximal tubule, Henle’s loop, the distal tubule, and the collecting duct. In the tubular system of the kidney, the composition of primary urine is modified by the reabsorption and secretion of ions and molecules to yield final excreted urine. The underlying membrane transport processes are mainly energy-consuming (active transport) and in some cases passive. Since active transport accounts for a large part of the cell’s ATP demands, it is an important target for AMPK. Here, we review the AMPK-dependent regulation of membrane transport along nephron segments and discuss physiological and pathophysiological implications.

Keywords: transporter; carrier; pump; membrane; energy deficiency

1. Introduction

The 5′-adenosine monophosphate (AMP)–activated protein kinase (AMPK) is a serine/threonine protein kinase that is evolutionarily conserved and functions as an intracellular energy sensor in mammalian cells [1–5]. It is a central regulator of energy homeostasis and affects many important cellular functions including growth, differentiation, autophagy, and metabolism [1,2,6]. During energy depletion when cellular AMP levels are high relative to the adenosine triphosphate (ATP) concentration, AMPK activates energy-providing pathways including glucose uptake, glycolysis, or fatty acid oxidation [7–10]. Simultaneously, processes consuming ATP (e.g., gluconeogenesis, lipogenesis, or protein synthesis) are inhibited [7–10].

Being expressed in most mammalian cells, AMPK is a heterotrimeric protein consisting of a catalytic α (α1 or α2), scaffolding β (β1 or β2), and a regulatory nucleotide-binding γ (γ1, γ2, or γ3) subunit with the expression pattern differing from cell type to cell type [1,2,11–14]. Induction of AMPK activity involves phosphorylation of the conserved threonine residue Thr172 within the activation loop of the α subunit’s kinase domain by various protein kinases including the tumor suppressor liver kinase B1 (LKB1), Ca^{2+}/calmodulin–dependent protein kinase β (CaM KKβ), and transforming growth factor beta-activated kinase 1 [1,15–28]. AMPK activation in cellular energy depletion is primarily mediated by an increase in the AMP/ATP or ADP/ATP ratio [8,29,30]. Thus, AMP or ADP binding to the subunit at cystathionine-beta-synthase repeats results in conformational changes that allows for the phosphorylation at Thr172 by LKB1. This results in an enhancement of AMPK activity by >100-fold [1,8,12,15,31–36]. Moreover, AMP or ADP binding prevents dephosphorylation at Thr172.
by protein phosphatases [8,12,37,38]. Additionally, binding of AMP, but not ADP, activates AMPK allosterically [8,11,12,37]. Conversely, ATP binding to the cystathionine-beta-synthase domain results in AMPK dephosphorylation by protein phosphatases [1,8,39].

Besides LKB1-associated regulation of AMPK phosphorylation, an alternative Ca\(^{2+}\)-involving activation mechanisms independent of AMP exists [6,12,40,41]. Protein kinase CaMKK\(\beta\) phosphorylates AMPK at Thr172 in response to elevated intracellular Ca\(^{2+}\) levels which may be caused by mediators such as thrombin or ghrelin [6,12,23,40,42,43]. Intracellular Ca\(^{2+}\) store depletion detected by the Ca\(^{2+}\)-sensing protein stromal interacting molecule-1 leads to store-operated Ca\(^{2+}\) entry (SOCE) involving the Ca\(^{2+}\) release-activated Ca\(^{2+}\) channel Orai1 [44–49]. Orai1-mediated SOCE impacts on many cellular functions including cell proliferation, differentiation, migration, and cytokine production [44,50–55]. SOCE is involved in a sort of feedback mechanism involving AMPK: SOCE activates AMPK through CaMKK\(\beta\). AMPK in turn inhibits SOCE [45]. Moreover, AMPK inhibits SOCE by regulating Orai1 membrane abundance (at least in UMR106 cells) [44,56].

AMPK is a major regulator of whole body energy homeostasis [10,12], impacting on a variety of organs including liver [57–61], skeletal [62–66] and cardiac muscle [67–73], kidney [74–77], and bone [78–80]. In the kidney, AMPK regulates epithelial transport, podocyte function, blood pressure, epithelial-to-mesenchymal transition, autophagy as well as nitric oxide synthesis [75,76,81–83]. Not surprisingly, AMPK is highly relevant for renal pathophysiology, including ischemia, diabetic renal hypertrophy, polycystic kidney disease, chronic kidney disease, and hypertension [40,67,74–76]. This review summarizes the contribution of AMPK to the regulation of renal transport and hence to the final composition of excreted urine. Moreover, pathophysiological implications are discussed.

2. AMPK and Renal Tubular Transport

The kidney is particularly relevant for fluid, electrolyte, and acid–base homeostasis. In addition, it is an endocrine organ producing different hormones such as erythropoietin, Klotho, and calcitriol, the active form of vitamin D [84–86]. The kidneys are made up of about 1 million nephrons, their functional elements. A nephron comprises the glomerulus surrounded by the Bowman’s capsule, the proximal tubule, Henle’s loop, distal tubule, and the collecting duct. The primary urine is filtered in the glomerulus. Its composition is similar to plasma. In general, large molecules and particularly proteins >6000 Dalton are normally filtered to a low extent, if at all. The renal tubular system modifies the primary urine by reabsorbing or secreting ions and molecules, ultimately yielding the final urine [85–87]. Epithelial transport is mainly dependent on ATP-dependent pumps (primary-active), secondary- or tertiary-active transporters, as well as carriers and channels (passive, facilitated diffusion). Since active transport consumes energy by definition, it is not surprising that it is subject to regulation by AMPK. Moreover, even passive transport involving glucose transporter (GLUT) carriers is controlled by AMPK [74,75].

2.1. Na\(^+\)/K\(^+\)-ATPase

The ubiquitously expressed Na\(^+\)/K\(^+\)-ATPase is a primary active ATP-driven pump that mediates the basolateral extrusion of 3Na\(^+\) in exchange of 2K\(^+\), thereby establishing a transmembrane Na\(^+\) gradient, which is the prerequisite for secondary active Na\(^+\)-dependent transport (e.g., through Na\(^+\)-dependent glucose cotransporter 1 and 2 (SGLT1/2), Na\(^+\)/H\(^+\) exchanger isoform 1 (NHE1), Na\(^+\)-coupled phosphate transporter (NaPi-IIa), or Na\(^+\)-K\(^+\)-2Cl\(^−\) cotransporter (NKCC2), as discussed below) [75,88–94]. Almost one-third of the body’s energy is consumed by this pump [95]. Therefore, it does make sense that it is regulated by AMPK [74–76,94]: AMPK inhibits Na\(^+\)/K\(^+\)-ATPase in airway epithelial cells by promoting its endocytosis [96–100]. However, AMPK stimulates Na\(^+\)/K\(^+\)-ATPase membrane expression in skeletal muscle cells [101] and in renal epithelia [102], thereby counteracting renal ischemia-induced Na\(^+\)/K\(^+\)-ATPase endocytosis [103]. Interestingly, AMPK\(\beta\)1 deficiency was found not to alter outcome in an ischemic kidney injury model in mice [104]. Hence, the effect of AMPK on Na\(^+\)/K\(^+\)-ATPase appears to be highly tissue-specific [74,75].
2.2. Proximal Tubule

A wide variety of luminal Na\(^{+}\)-dependent cotransporters, which are secondary active, are involved in epithelial transport in the proximal tubule. Secondary active transporters utilize the energy of the transmembrane Na\(^{+}\) gradient generated by the primary active ATP-consuming Na\(^{+}\)/K\(^{+}\)-ATPase to facilitate transport of a substrate against its concentration gradient [105,106]. These transporters and the basolateral Na\(^{+}\)/K\(^{+}\)-ATPase consume substantial amounts of total cellular energy [74,75,107]. Hence, AMPK has been demonstrated to be an important regulator of proximal tubule transport [74,75].

2.2.1. Glucose Transport

Since glucose is freely filtered by the glomerulus, glucose concentration in primary urine is similar to the plasma glucose concentration, whereas excreted urine is usually free of glucose [108–110]. The sugar is reabsorbed in the proximal tubule by the Na\(^{+}\)-dependent glucose cotransporter 1 and 2 (SGLT1 and 2), the different expression patterns and properties of which ensure total glucose reabsorption as long as the plasma glucose concentration is not abnormally high [89,108]. SGLT2 has a high transport capacity but low affinity for glucose and is predominantly expressed in the kidney, while SGLT1 is also expressed in other tissues including the small intestine. SGLT2 contributes to the reabsorption of up to 90% of filtered glucose [108,109,111,112]. On the other hand, AMPK-regulated SGLT1 [7,92,113] has a low transport capacity but high affinity for glucose and reabsors the remaining glucose [108–110,114,115]. Glucose leaves the basolateral membrane through passive glucose carriers GLUT1 and GLUT2 [108,116–118]. AMPK activates SGLT1-dependent glucose transport, presumably by stimulating membrane insertion of the cotransporter as observed in colorectal Caco-2 cells [92,119]. In line with this, AMPK activation is associated with increased SGLT1 expression and glucose uptake in cardiomyocytes [113,120]. Although the AMPK-dependent regulation of SGLT1 in the proximal tubule has not explicitly been addressed, it is tempting to speculate that it is similar to other cell types [92,113,119,120]. The regulation of SGLT by AMPK is a doubled-edged sword: on the one hand, SGLT1-dependent reabsorption of glucose in proximal tubular cells requires energy which is generated by β-oxidation of fatty acids to a large extent [121,122]. On the other hand, it prevents the loss of energy-rich glucose [122,123], thereby maintaining the Na\(^{+}\)/K\(^{+}\)-ATPase-facilitated Na\(^{+}\) gradient for Na\(^{+}\)-dependent transport and many other cellular processes [75,76]. SGLT1-mediated glucose uptake is linked to the GLUT1-dependent efflux at the basolateral side [108,116]. GLUT1 activity is stimulated by AMPK in various cell types [124–131]. Therefore, it is conceivable that renal GLUT1 might also be regulated by AMPK in order to save energy-providing glucose. In line with this, Baldwin et al. (1997) showed enhanced glucose uptake via GLUT1 in baby hamster kidney cells treated with AMPK activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) [132]. Moreover, Sokolovska et al. (2010) reported that metformin, another pharmacological AMPK activator, increased GLUT1 gene expression in rat kidneys [133]. Also, AMPK activation was associated with enhanced activity of GLUT2. These studies, however, found reduced SGLT1 membrane abundance upon AMPK activation, at least in the case of murine intestinal tissue [134,135].

2.2.2. Na\(^{+}\)/H\(^{+}\) Exchanger Isoform 1

The ubiquitous Na\(^{+}\)/H\(^{+}\) exchanger isoform 1 (NHE1) participates in cell volume and pH regulation by extruding one cytosolic H\(^{+}\) in exchange for one extracellular Na\(^{+}\) [136,137]. NHE1 is expressed in all parts of the nephron, including the proximal tubule. However, it cannot be detected in the macula densa and intercalated cells of the distal nephron [136,138,139]. In the proximal tubule, NHE1 is particularly important for HCO\(_3\)\(^{-}\) reabsorption [140]. In hypoxia, anaerobic glycolysis is predominant, which results in intracellular accumulation of lactate and H\(^{+}\) [90]. Acidosis, however, inhibits glycolysis [90,141,142] and would jeopardize cellular energy generation. AMPK-dependent stimulation of NHE1 activity in human embryonic kidney (HEK) cells therefore helps cells keep up anaerobic glycolysis in oxygen deficiency, as demonstrated by Rotte et al. (2010) [90]. Given that NHE1
is needed for proximal tubular HCO$_3^-$ reabsorption [140], AMPK may help retain HCO$_3^-$, thereby alleviating acidosis in energy deficiency and hypoxia.

2.2.3. Creatine Transporter

In some organs with high metabolic activity, including skeletal muscle, heart, and brain, creatine is used to refuel cellular ATP levels [143–145]. In the proximal tubule, creatine, a small molecule that is freely filtered, is also reabsorbed through secondary active Na$^+$-dependent creatine transporter (CRT) (SLC6A8) [7,75,143,146]. AMPK has been demonstrated to downregulate CRT activity and apical membrane expression in a polarized mouse S3 proximal tubule cell line, presumably through mammalian target of rapamycin signaling [147]. The AMPK-dependent inhibition of CRT may help reduce unnecessary energy expenditure [75]. Conversely, AMPK stimulates CRT-mediated creatine transport in cardiomyocytes [148,149]. This again demonstrates that AMPK effects are tissue-specific [148].

2.2.4. Na$^+$-Coupled Phosphate Transporter IIa

Inorganic phosphate is mainly reabsorbed by the secondary active Na$^+$-coupled phosphate transporter (NaPi-IIa) (SLC34A1) in the proximal tubule [93,150–152]. Employing electrophysiological recordings in Xenopus oocytes, it was shown that AMPK inhibits NaPi-IIa [93]. Kinetics analysis revealed that AMPK decreases NaPi-IIa membrane expression rather than changing its properties. The regulation of phosphate metabolism by AMPK is not restricted to NaPi-IIa: Recently, AMPK was demonstrated to control the formation of bone-derived hormone fibroblast growth factor 23 (FGF23) [56], which induces renal phosphate excretion by extracellular-signal regulated kinases 1/2 (ERK1/2)-mediated degradation of membrane NaPi-IIa [150]. AMPK inhibits FGF23 production in cell culture and in mice [56]. Despite markedly elevated FGF23 serum levels in AMPKα1-deficient mice, renal phosphate excretion was not different from wild-type animals [36]. The same holds true for cellular localization of NaPi-IIa and renal ERK1/2 [56]. Thus, it is possible that AMPK deficiency is paralleled with some FGF23 resistance.

2.3. Loop of Henle

2.3.1. Na$^+$-K$^+$-2Cl$^-$ Cotransporter

The Na$^+$-K$^+$-2Cl$^-$ cotransporter (NKCC2), expressed in the thick ascending limb (TAL) of the loop of Henle and macula densa, is required for the generation of a hypertonic medullary interstitium, a mechanism needed for concentrating urine [75,76,88,91]. NKCC2 is a direct substrate of AMPK which phosphorylates it at its stimulatory serine residue Ser-126 [153]. Moreover, exposure of murine macula densa-like cells to low salt leads to AMPK activation and increased NKCC2 phosphorylation [154]. In addition, increased subapical expression (and apparent reduced apical expression) of NKCC2 in the medullary TAL of the loop of Henle along with elevated urinary Na$^+$ excretion in AMPKβ1-deficient mice on a normal salt diet were observed [155]. This is in line with AMPK being an important regulator of NKCC2-mediated salt retention in the medullary TAL of Henle [155]. Efe et al. (2016) recently observed markedly increased outer medullary expression of NKCC2 in rats treated with the AMPK activator metformin [156]. However, according to a recent in vivo study by Udwan et al. (2017), a low salt diet induced upregulation of NKCC2 surface expression in mouse kidneys but left AMPK activity unchanged [157]. Therefore, the exact role of AMPK in stimulating NKCC2 remains to be established.

2.3.2. Renal Outer Medullary K$^+$ Channel

The apical renal outer medullary K$^+$ channel (ROMK) is required for NKCC2 to work properly, as it allows the recirculation of K$^+$ ions taken up by NKCC2 into the lumen [75,88]. AMPK is an inhibitor of ROMK by downregulating both channel activity and membrane abundance of the channel protein in a heterologous expression system using Xenopus oocytes [158]. In vivo studies revealed that the AMPK
effect on ROMK is relevant for the renal excretion of K⁺ after an acute K⁺ challenge, as upregulation of renal ROMK1 protein expression and the ability of K⁺ elimination were more pronounced in AMPKα1-deficient than in wild-type mice [158].

2.4. Distal Tubule

2.4.1. Cystic Fibrosis Transmembrane Conductance Regulator

The ATP-gated and cyclic AMP (cAMP)-dependent Cl⁻ channel cystic fibrosis transmembrane conductance regulator (CFTR) participates in Cl⁻ secretion and is broadly known for its role in cystic fibrosis, the pathophysiology of which is due to channel malfunction [74–76,159]. In the kidney, CFTR contributes to Cl⁻ secretion in the distal tubule and the principal cells of the cortical and medullary collecting ducts [74,75,160]. AMPK has been demonstrated to inhibit CFTR-dependent Cl⁻ conductance in *Xenopus* oocytes [159] and to decrease CFTR channel activity in the lung [161,162] and colon [163]. cAMP-stimulated cell proliferation and CFTR-dependent Cl⁻ secretion play a decisive role for epithelial cyst enlargement in autosomal dominant polycystic kidney disease (ADPKD) [164]. In line with this, AMPK activation inhibits CFTR in Madin-Darby canine kidney (MDCK) cells [165] as well as decreases cystogenesis in murine models of ADPKD [165,166], suggesting a potential role for pharmacological AMPK activation in the treatment of ADPKD [165,166].

2.4.2. Ca²⁺ Transport

Most Ca²⁺ is reabsorbed by passive paracellular diffusion along with other ions and water through tight junctions in the proximal tubule and the more distal parts of the nephron [88,167]. Conversely, only 5–10% of filtered Ca²⁺ is reabsorbed by transcellular transport involving the apical transient receptor potential vanilloid 5 channel TRPV5 in the distal convoluted tubule [88]: Ca²⁺ enters the cell through TRPV5, whereas basolateral Ca²⁺ efflux is accomplished by the Na⁺/Ca²⁺ exchanger (NCX) and the Ca²⁺-ATPase [88,167,168]. AMPK has been shown to inhibit NCX and decrease Orai1-mediated SOCE in murine dendritic cells [169]. Therefore, it is tempting to speculate that Ca²⁺ reabsorption may be downregulated in the distal tubule in ATP deficiency [169,170]. Indeed, AMPK downregulates Orai1-dependent SOCE in T-lymphocytes [171], endothelial cells [45], and in osteoblast-like cells [56]. Since renal Orai1 activity contributes to kidney fibrosis [172], AMPK-mediated Orai1 downregulation may also be therapeutically desirable.

2.5. Collecting Duct

2.5.1. Epithelial Na⁺ Channel

In the collecting duct, fine tuning of Na⁺ and K⁺ homeostasis is accomplished by epithelial Na⁺ channel (ENaC) and ROMK K⁺ channel. Both channels are controlled by the renin-angiotensin-aldosterone system [173–175] regulating extracellular volume and hence arterial blood pressure [173–177]. Na⁺ reabsorption by ENaC in the late distal convoluted tubule and cortical collecting duct principal cells is a highly energy-demanding process, as it utilizes the electrochemical driving force generated by the basolateral Na⁺/K⁺-ATPase [74–76,176,178]. AMPK inhibits epithelial Na⁺ transport in various tissues, including lung [96,179], colonic [180], and renal cortical collecting duct cells [180–183]. In line with this, AMPKα1-deficient mice exhibit increased renal ENaC expression [180]. In detail, AMPK downregulates ENaC surface expression by inducing the binding of the ubiquitin ligase neural precursor cell expressed developmentally downregulated protein 4-2 (Nedd4-2) to ENaC subunits, resulting in ENaC ubiquitination with subsequent endocytosis and degradation [177,180,184]. In line with this, activation of AMPK enhances the tubuloglomerular feedback and induces urinary diuresis and Na⁺ excretion in rats [185]. However, AMPKα1⁻/⁻ mice with genetic kidney-specific AMPKα2 deletion exhibit a moderate increase in diuresis and natriuresis, possibly because NKCC2
activity is insufficient despite upregulated ENaC activity [186]. Taken together, AMPK activity limits ENaC-dependent energy-consuming Na\(^+\) reabsorption [177,180,181,185].

2.5.2. Voltage-Gated K\(^+\) Channel

The voltage-gated K\(^+\) channel (KCNQ1) is important for the cardiovascular system as well as for electrolyte and fluid homeostasis and is expressed in the distal nephron including the collecting duct [170,187–189]. Its exact role is ill-defined, although a contribution to cell volume regulation is postulated [75,187]. Similar to ENaC, AMPK inhibits KCNQ1 via Nedd4-2, as demonstrated in collecting duct principal cells of rat ex vivo kidney slices [187], MDCK cells [190], and Xenopus oocytes [191].

2.5.3. Vacuolar H\(^+\)-ATPase

The primary active vacuolar H\(^+\)-ATPase (V-ATPase) is located at the apical membrane of proximal tubule cells and collecting duct type A intercalated cells. It contributes to the regulation of acid–base homeostasis by secreting H\(^+\) ions into the tubular lumen [76,192,193]. AMPK inhibits the protein kinase A (PKA)-dependent membrane expression of V-ATPase in collecting duct intercalated cells of rat ex vivo kidney slices [193]. Moreover, epididymal proton-secreting clear cells, developmentally related to intercalated cells, exhibit reduced apical membrane abundance of V-ATPase after in vivo perfusion with the AMPK activator 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) into rats [194]. It appears to be likely that energy deficiency limits highly energy-consuming primary active H\(^+\) excretion in the proximal tubule, whereas secondary active NHE1-dependent H\(^+\) secretion is maintained, thereby keeping up at least anaerobic glycolysis [192]. The opposing effects of AMPK and PKA on V-ATPase expression and activity in kidney intercalated cells can be explained by different phosphorylation sites, as AMPK and PKA phosphorylate the A subunit at Ser-384 and Ser-175, respectively [195,196]. McGuire and Forgac (2018) further demonstrated that AMPK increases lysosomal V-ATPase assembly and activity in HEK293T cells under conditions of energy depletion [197]. In cells depleted of energy, acidification of autophagic intracellular compartments by V-ATPases enables the lysosomal degradation of proteins and lipids to generate energy substrates for ATP production [197,198]. Thus, it appears to be likely that AMPK-regulated V-ATPase activity depends on its concrete cellular localization and function [197].

2.5.4. Water and Urea Handling

AMPK also regulates renal urea and water handling [76,199]. In the inner medullary collecting duct, osmotic gradients are generated by NKCC2 and urea transporter UT-A1 and water is reabsorbed through aquaporin 2 (AQP2) [76,156,199,200]. The concentration of urine requires the antidiuretic hormone vasopressin, which binds to vasopressin type 2 receptors of collecting duct principal cells, resulting in cAMP-mediated activation of PKA and subsequent phosphorylation and apical membrane insertion of AQP2 and UT-A1 [76,156,199]. Congenital nephrogenic diabetes insipidus (NDI) is a disease primarily caused by mutations of vasopressin type 2 receptors that is characterized by renal resistance to vasopressin and limited urine concentrating capacity [156,201]. According to two in vivo studies using rodent models of congenital NDI, the metformin-stimulated AMPK activation ameliorates the ability of the kidney to concentrate urine by increasing the phosphorylation and apical membrane expression of inner medullary AQP2 and UT-A1 [76,156,199]. In contrast, an ex vivo treatment of rat kidney slices with AICAR led to reduced apical membrane insertion of AQP2 [203]. Moreover, AMPK antagonizes the desmopressin-induced AQP2 phosphorylation in vitro, thus also suggesting an inhibitory function of AMPK on AQP2 regulation [203]. It appears likely that AMPK-independent effects of the pharmacological AMPK agonists contribute to this discrepancy [156,202,203]. Thus, further studies are clearly required.
3. Conclusions and Perspectives

A growing list of studies indicates the pivotal role of AMPK as a metabolic-sensing regulator of a multitude of transport processes in the kidney [7,74–76,170]. Particularly, AMPK activation under conditions of energy deficiency is expected to differentially modulate renal epithelial ion transport in order to preserve cellular energy homeostasis (Figure 1) [7,74–76,94,170]. Alongside the above discussed function of AMPK in kidney tubular transport, a variety of other transport proteins, which are expressed in the kidney as well, are regulated by AMPK in extrarenal tissues [7,94,170,204] that are reviewed elsewhere [170] and [7] and summarized in Table 1. Future studies are required to focus on the therapeutic value of pharmacological AMPK manipulation to combat kidney disease [74–76,205,206].

**Figure 1.** Tentative model illustrating AMPK-dependent effects on renal transport along the nephron. Cellular energy depletion (e.g., during hypoxia) leads to an elevated AMP/ATP ratio and subsequent AMPK activation. AMPK in turn regulates a multitude of active and passive epithelial transport processes along the renal tubular system in order to maintain cellular energy homeostasis. Ion channels, transport proteins, and ATPases that are activated upon AMPK stimulation are depicted as green icons, whereas red coloring indicates AMPK-dependent inhibition (see text for details). AMP, 5’-adenosine monophosphate; AMPK, AMP-activated protein kinase; SGLT1, Na+-dependent glucose cotransporter 1; V-ATPase, vacuolar H+-ATPase; CRT, creatine transporter; NaPi-IIa, Na+-coupled phosphate transporter IIa; NHE1, Na+/H+ exchanger isoform 1; GLUT1, glucose transporter 1; NKCC2, Na+-K+-2Cl− cotransporter; ROMK, renal outer medullary K+ channel; CFTR, cystic fibrosis transmembrane conductance regulator; ENaC, epithelial Na+ channel; KCNQ1, voltage-gated K+ channel; Nedd4-2, neural precursor cell expressed developmentally downregulated protein 4-2; UT-A1, urea transporter A1; AQP2, aquaporin 2.
Table 1. Overview of transport proteins regulated by AMPK in extrarenal tissues and evidence for renal expression.

| Ion Channel/Transporter and Method of Modifying AMPK Activity | AMPK Effect | Cell Type of Studied AMPK Effect/Ref. | Evidence for Renal Expression/Ref. |
|---------------------------------------------------------------|-------------|--------------------------------------|----------------------------------|
| **Heterologous expression systems**                           |             |                                      |                                  |
| *Kir2.1*                                                      | Reduction of channel activity and membrane abundance via Nedd4-2 mediated endocytosis | Xenopus oocytes [207] | Human proximal tubular cells [208] |
| *Kv1.5*                                                      | Reduction of channel activity and membrane abundance via Nedd4-2 mediated endocytosis | Xenopus oocytes [209] | Human kidney biopsies [210] |
| *Kv11.1 (hERG)*                                              | Reduction of channel activity and membrane abundance via Nedd4-2 mediated endocytosis | Xenopus oocytes [211] | Human proximal and distal convoluted tubule [212] |
| *SMIT*                                                       | Reduction of channel activity | Xenopus oocytes [213] | Rat kidney medulla [214] |
| *BGT1*                                                       | Reduction of channel activity | Xenopus oocytes [213] | Human kidney inner medulla [215] and mouse kidney medulla (basolateral membranes of collecting ducts and TAL of Henle) [216] |
| *EAAT3*                                                      | Reduction of channel activity and membrane abundance | Xenopus oocytes [217] | Mouse renal proximal tubule [218] |
| *NCX*                                                        | Reduction of channel activity and membrane abundance | Xenopus oocytes [169] | Rat distal convoluted tubule [219] |
| *K_{Ca}10.1 (TREK-2)*                                       | Inhibition of channel activity via phosphorylation at Ser-326 and Ser-359 | HEK293 cells [220] | Human proximal tubule [221] |
| *K_{Ca}1.1*                                                  | Increase in channel activity and membrane abundance | Xenopus oocytes [222] | Human clear cell renal cell carcinoma (ccRCC) and healthy kidney cortex [223] |
| **Pharmacological Manipulation**                             |             |                                      |                                  |
| *K_{Ca}1.1*                                                  | Inhibition of channel activity | Rat carotid body type I cells [224] |                                  |
| *Kir6.2*                                                     | Up- or down-regulation of channel activity | Rat cardiomyocytes [225] | Rat renal tubular epithelial cells [228] |
| *KCa3.1*                                                     | Reduction of channel activity | Human airway epithelial cells [229] | Human proximal tubular cells [230] |
| *MCT1 and MCT4*                                              | Upregulation of mRNA expression | Rat skeletal muscle [231] | MCT1: basolateral membrane of mouse proximal tubular epithelial cells [232] MCT4: human ccRCC [233] |
| *PepT1*                                                      | Downregulation of channel activity and brush-border membrane abundance | Caco-2 cells [234] | Rat renal proximal tubule [235] |
| *Orai1*                                                      | Downregulation of cell membrane abundance and SOCE | Rat UMR106 osteoblast-like cells [56] | Rat glomerular mesangial cells [236] |
| **Genetically Modified Mouse Models**                        |             |                                      |                                  |
| *Orai1*                                                      |                                      | Mouse T-lymphocytes [171] |                                  |
|                                                               |                                      | Mouse dendritic cells [169] |                                  |
Author Contributions: P.G. and M.F. wrote this review.

Funding: The authors were supported by the Deutsche Forschungsgemeinschaft (DFG; Fo695/2-1).

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| ADP          | Adenosine diphosphate |
| ADPKD        | Autosomal dominant polycystic kidney disease |
| AMPK         | 5′-adenosine monophosphate (AMP)–activated protein kinase |
| AQP2         | Aquaporin 2 |
| ATP          | Adenosine triphosphate |
| BGT1         | Betaine/γ-aminobutyric acid (GABA) transporter 1 |
| CaMKKβ       | Ca2+/calmodulin–dependent protein kinase kinase β |
| cAMP         | Cyclic adenosine monophosphate |
| ccRCC        | Clear cell renal cell carcinoma |
| CFTR         | Cystic fibrosis transmembrane conductance regulator |
| CRT          | Creatine transporter |
| EAAT3        | Excitatory amino acid transporter 3 |
| ENaC         | Epithelial Na+ channel |
| ERK1/2       | Extracellular-signal regulated kinases 1/2 |
| FGF23        | Fibroblast growth factor 23 |
| GLUT         | Glucose transporter |
| HEK          | Human embryonic kidney cells |
| hERG         | Human ether-a-go-go-related gene |
| Kca          | Ca2+ activated K+ channels |
| KCNQ1        | Voltage-gated K+ channel |
| Kir          | Inwardly rectifying K+ channels |
| Kv           | Voltage gated K+ channels |
| LKB1         | Liver kinase B1 |
| MCT          | Monocarboxylate transporters |
| MDCK         | Madin-Darby canine kidney cells |
| NaPi-IIa      | Na+–coupled phosphate transporter |
| NCX          | Na+/Ca2+ exchanger |
| NDI          | Nephrogenic diabetes insipidus |
| Nedd4-2      | Neural precursor cell expressed developmentally down-regulated protein 4-2 |
| NHE1         | Na+/H+ exchanger isoform 1 |
| NKCC2        | Na+/K+–2Cl− cotransporter |
| PepT1        | H+–coupled di- and tripeptide transporter 1 |
| PKA          | Protein kinase A |
| ROMK         | Renal outer medullary K+ channel |
| SGLT         | Na+–dependent glucose cotransporter |
| SMIT         | Na+ coupled myoinositol transporter |
| SOCE         | Store-operated Ca2+ entry |
| TAL          | Thick ascending limb |
| TREK-2       | Tandem pore domain K+ channel 2 |
| TRPV5        | Transient receptor potential vanilloid 5 channel |
| UT           | Urea transporter |
| V-ATPase     | Vacuolar H+–ATPase |
References

1. Ramesh, M.; Vepuri, S.B.; Oosthuizen, F.; Soliman, M.E. Adenosine Monophosphate-Activated Protein Kinase (AMPK) as a Diverse Therapeutic Target: A Computational Perspective. Appl. Biochem. Biotechnol. 2016, 178, 810–830. [CrossRef] [PubMed]

2. Mihaylova, M.M.; Shaw, R.J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 2011, 13, 1016–1023. [CrossRef] [PubMed]

3. Hardie, D.G. The AMP-activated protein kinase—New players upstream and downstream. J. Cell Sci. 2004, 117, 5479–5487. [CrossRef] [PubMed]

4. Viollet, B. AMPK: Lessons from transgenic and knockout animals. Front. Biosci. 2009, 14, 19–44. [CrossRef]

5. Viollet, B.; Andreelli, F.; Jørgensen, S.B.; Perrin, C.; Flamez, D.; Mu, J.; Wojtaszewski, J.F.P.; Schuit, F.C.; Birnbaum, M.; Richter, E.; et al. Physiological role of AMP-activated protein kinase (AMPK): Insights from knockout mouse models. Biochem. Soc. Trans. 2003, 31, 216–219. [CrossRef]

6. Hardie, D.G.; Schaffer, B.E.; Brunet, A. AMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs. Trends Cell Biol. 2016, 26, 190–201. [CrossRef] [PubMed]

7. Dërmaku-Sopjani, M.; Abazi, S.; Faggio, C.; Kolgeci, J.; Sopjani, M. AMPK-sensitive cellular transport. J. Biochem. 2014, 155, 147–158. [CrossRef] [PubMed]

8. Hardie, D.G. AMPK—Sensing energy while talking to other signalling pathways. Cell Metab. 2014, 20, 939–952. [CrossRef] [PubMed]

9. Hardie, D.G.; Carling, D.; Gamblin, S.J. AMP-activated protein kinase: Also regulated by ADP? Trends Biochem. Sci. 2011, 36, 470–477. [CrossRef] [PubMed]

10. Hardie, D.G.; Ross, F.A.; Hawley, S.A. AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 2012, 13, 251–262. [CrossRef] [PubMed]

11. Ross, F.A.; Jensen, T.E.; Hardie, D.G. Differential regulation by AMP and ADP of AMPK complexes containing different γ subunit isoforms. Biochem. J. 2016, 473, 189–199. [CrossRef] [PubMed]

12. Hardie, D.G.; Lin, S.-C. AMP-activated protein kinase—Not just an energy sensor. F1000Research 2017, 6, 1724. [CrossRef] [PubMed]

13. Thornton, C.; Snowden, M.A.; Carling, D. Identification of a novel AMP-activated protein kinase β subunit isoform that is highly expressed in skeletal muscle. J. Biol. Chem. 1998, 273, 12443–12450. [CrossRef] [PubMed]

14. Viollet, B.; Andreelli, F.; Jørgensen, S.B.; Perrin, C.; Geloen, A.; Flamez, D.; Mu, J.; Lenzner, C.; Baud, O.; Bennoun, M.; et al. The AMP-activated protein kinase α2 catalytic subunit controls whole-body insulin sensitivity. J. Clin. Invest. 2003, 111, 91–98. [CrossRef] [PubMed]

15. Hawley, S.A.; Davison, M.; Woods, A.; Davies, S.P.; Beri, R.K.; Carling, D.; Hardie, D.G. Characterization of the AMP-activated Protein Kinase Kinase from Rat Liver and Identification of Threonine 172 as the Major Site at Which It Phosphorylates AMP-Activated Protein Kinase. J. Biol. Chem. 1996, 271, 27879–27887. [CrossRef] [PubMed]

16. Woods, A.; Johnstone, S.R.; Dickerson, K.; Leiper, F.C.; Fryer, L.G.D.; Neumann, D.; Schlattner, U.; Wallimann, T.; Carlson, M.; Carling, D. LKB1 Is the Upstream Kinase in the AMP-Activated Protein Kinase Cascade. J. Biol. Chem. 2003, 278, 2004–2008. [CrossRef] [PubMed]

17. Woods, A.; Johnstone, S.R.; Dickerson, K.; Leiper, F.C.; Fryer, L.G.D.; Neumann, D.; Schlattner, U.; Wallimann, T.; Carlson, M.; Carling, D. Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc. Natl. Acad. Sci. USA 2003, 100, 8839–8843. [CrossRef] [PubMed]

18. Shaw, R.J.; Kosmatka, M.; Bardeesy, N.; Hurley, R.L.; Witters, L.A.; DePinho, R.A.; Cantley, L.C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. USA 2004, 101, 3329–3335. [CrossRef] [PubMed]

19. Herrero-Martín, G.; Hayer-Hansen, M.; García-García, C.; Fumarola, C.; Farkas, T.; López-Rivas, A.; Jäättelä, M. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J. 2009, 28, 677–685. [CrossRef] [PubMed]
21. Momcilovic, M.; Hong, S.-P.; Carlson, M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J. Biol. Chem. 2006, 281, 25336–25343. [CrossRef] [PubMed]

22. Fujiwara, Y.; Kawaguchi, Y.; Fujimoto, T.; Kanayama, N.; Magari, M.; Tokumitsu, H. Differential AMP-activated Protein Kinase (AMPK) Recognition Mechanism of Ca\(^{2+}\)/Calmodulin-dependent Protein Kinase Isoforms. J. Biol. Chem. 2016, 291, 13802–13808. [CrossRef] [PubMed]

23. Hawley, S.A.; Pan, D.A.; Mustard, K.J.; Ross, L.; Bain, J.; Edelman, A.M.; Frenguelli, B.G.; Hardie, D.G. Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2005, 2, 9–19. [CrossRef] [PubMed]

24. Hurley, R.L.; Anderson, K.A.; Franzone, J.M.; Kemp, B.E.; Means, A.R.; Witters, L.A. The Ca\(^{2+}\)/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J. Biol. Chem. 2005, 280, 29060–29066. [CrossRef] [PubMed]

25. Burkewitz, K.; Zhang, Y.; Mair, W.B. AMPK at the nexus of energetics and aging. Cell Metab. 2014, 20, 10–25. [CrossRef] [PubMed]

26. Neumann, D. Is TAK1 a Direct Upstream Kinase of AMPK? Int. J. Mol. Sci. 2018, 19, 2412. [CrossRef] [PubMed]

27. Zhu, X.; Dahlmans, V.; Thali, R.; Preisinger, C.; Viollet, B.; Voncken, J.W.; Neumann, D. AMP-activated Protein Kinase Up-regulates Mitogen-activated Protein (MAP) Kinase-interacting Serine/Threonine Kinase 1a-dependent Phosphorylation of Eukaryotic Translation Initiation Factor 4E. J. Biol. Chem. 2016, 291, 17020–17027. [CrossRef] [PubMed]

28. Viollet, B.; Foretz, M. Revisiting the mechanisms of metformin action in the liver. Ann. Endocrinol. 2013, 74, 123–129. [CrossRef] [PubMed]

29. Sakamoto, K.; Göransson, O.; Hardie, D.G.; Alessi, D.R. Activity of LKB1 and AMPK-related kinases in skeletal muscle: Effects of contraction, phenformin, and AICAR. Am. J. Physiol. Endocrinol. Metab. 2004, 287, E310–E317. [CrossRef] [PubMed]

30. Sakamoto, K.; McCarthy, A.; Smith, D.; Green, K.A.; Grahame Hardie, D.; Ashworth, A.; Alessi, D.R. Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J. 2005, 24, 1810–1820. [CrossRef] [PubMed]

31. Cheung, P.C.F.; Salt, I.P.; Davies, S.P.; Hardie, D.G.; Carling, D. Characterization of AMP-activated protein kinase γ-subunit isoforms and their role in AMP binding. Biochem. J. 2000, 346, 659–669. [CrossRef] [PubMed]

32. Sanders, M.J.; Grondin, P.O.; Hegarty, B.D.; Snowden, M.A.; Carling, D. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem. J. 2007, 403, 139–148. [CrossRef] [PubMed]

33. Xiao, B.; Sanders, M.J.; Underwood, E.; Heath, R.; Mayer, F.V.; Carmena, D.; Jing, C.; Walker, P.A.; Eccleston, J.F.; Haire, L.F.; et al. Structure of mammalian AMPK and its regulation by ADP. Nature 2011, 472, 230–233. [CrossRef] [PubMed]

34. Oakhill, J.S.; Chen, Z.-P.; Scott, J.W.; Steel, R.; Castelli, L.A.; Ling, N.; Macaulay, S.L.; Kemp, B.E. β-Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). Proc. Natl. Acad. Sci. USA 2010, 107, 19237–19241. [CrossRef] [PubMed]

35. Oakhill, J.S.; Steel, R.; Chen, Z.-P.; Scott, J.W.; Ling, N.; Tam, S.; Kemp, B.E. AMPK is a direct adenylate charge-regulated protein kinase. Science 2011, 332, 1433–1435. [CrossRef] [PubMed]

36. Viollet, B.; Mounier, R.; Leclerc, J.; Yazigi, A.; Foretz, M.; Andreelli, F. Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metab. 2007, 33, 395–402. [CrossRef] [PubMed]

37. Gowans, G.J.; Hawley, S.A.; Ross, F.A.; Hardie, D.G. AMP Is a True Physiological Regulator of AMP-Activated Protein Kinase by Both Allosteric Activation and Enhancing Net Phosphorylation. Cell Metab. 2013, 18, 556–566. [CrossRef] [PubMed]

38. Davies, S.P.; Helps, N.R.; Cohen, P.T.; Hardie, D.G. 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C α and native bovine protein phosphatase-2A c. FEBS Lett. 1995, 377, 421–425. [PubMed]
39. Chen, L.; Wang, J.; Zhang, Y.-Y.; Yan, S.F.; Neumann, D.; Schlattner, U.; Wang, Z.-X.; Wu, J.-W. AMP-activated protein kinase undergoes nucleotide-dependent conformational changes. *Nat. Struct. Mol. Biol.* 2012, 19, 716–718. [CrossRef] [PubMed]

40. Garcia, D.; Shaw, R.J. AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance. *Mol. Cell.* 2017, 66, 789–800. [CrossRef] [PubMed]

41. Woods, A.; Dickerson, K.; Heath, R.; Hong, S.-P.; Momcilovic, M.; Johnstone, S.R.; Carlson, M.; Carling, D. Ca\(^{2+}\)/calmodulin-dependent protein kinase is upstream of AMP-activated protein kinase in mammalian cells. *Cell Metab.* 2005, 2, 21–33. [CrossRef] [PubMed]

42. Stahmann, N.; Woods, A.; Carling, D.; Heller, R. Thrombin activates AMP-activated protein kinase in endothelial cells via a pathway involving Ca\(^{2+}\)/calmodulin-dependent protein kinase β. *Mol. Cell. Biol.* 2006, 26, 5933–5945. [CrossRef] [PubMed]

43. Yang, Y.; Atasoy, D.; Su, H.H.; Sternson, S.M. Hunger states switch a flip-flop memory circuit via a synaptic AMPK-dependent positive feedback loop. *Cell* 2011, 146, 992–1003. [PubMed]

44. Lang, F.; Eylenstein, A.; Shumilina, E. Regulation of Orai1/STIM1 by the kinases SGK1 and AMPK. *Cell Calcium* 2012, 52, 347–354. [CrossRef] [PubMed]

45. Sundivakkam, P.C.; Natarajan, V.; Malik, A.B.; Tiruppathi, C. Store-operated Ca\(^{2+}\) entry (SOCE) induced by protease-activated receptor-1 mediates STIM1 protein phosphorylation to inhibit SOCE in endothelial cells through AMP-activated protein kinase and p38β mitogen-activated protein kinase. *J. Biol. Chem.* 2013, 288, 17030–17041. [CrossRef] [PubMed]

46. Zhang, B.; Yan, J.; Umbach, A.T.; Fakhri, H.; Fajol, A.; Schmidt, S.; Salker, M.S.; Chen, H.; Alexander, D.; Spichig, D.; et al. NFκB-sensitive Orai1 expression in the regulation of FGF23 release. *J. Mol. Med.* 2016, 94, 557–566. [CrossRef] [PubMed]

47. Prakriya, M.; Feske, S.; Gwack, Y.; Srikanth, S.; Rao, A.; Hogan, P.G. Orai1 is an essential pore subunit of the CRAC channel. *Nature* 2006, 443, 230–233. [CrossRef] [PubMed]

48. Zhang, S.L.; Kozak, J.A.; Jiang, W.; Yeromin, A.V.; Chen, J.; Yu, Y.; Penna, A.; Shen, W.; Chi, V.; Cahalan, M.D. Store-dependent and -independent modes regulating Ca\(^{2+}\) release-activated Ca\(^{2+}\) channel activity of human Orai1 and Orai3. *J. Biol. Chem.* 2008, 283, 17662–17671. [CrossRef] [PubMed]

49. Tiruppathi, C.; Ahmmed, G.U.; Vogel, S.M.; Malik, A.B. Ca\(^{2+}\) signaling, TRP channels, and endothelial permeability. *Microcirculation* 2006, 13, 693–708. [CrossRef] [PubMed]

50. Yu, F.; Sun, L.; Machaca, K. Constitutive recycling of the store-operated Ca\(^{2+}\) channel Orai1 and its internalization during meiosis. *J. Cell Biol.* 2010, 191, 523–535. [CrossRef] [PubMed]

51. Baryshnikov, S.G.; Pulina, M.V.; Zulian, A.; Linde, C.I.; Golovina, V.A. Orai1, a critical component of store-operated Ca\(^{2+}\) entry, is functionally associated with Na\(^{+}/Ca\(^{2+}\) exchanger and plasma membrane Ca\(^{2+}\) pump in proliferating human arterial myocytes. *Am. J. Physiol. Cell Physiol.* 2009, 297, C1103–C1112. [CrossRef] [PubMed]

52. Johnstone, L.S.; Graham, S.J.L.; Dziadek, M.A. STIM proteins: Integrators of signaling pathways in development, differentiation and disease. *J. Cell. Mol. Med.* 2010, 14, 1890–1903. [CrossRef] [PubMed]

53. Yang, S.; Zhang, J.J.; Huang, X.-Y. Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. *Cancer Cell* 2009, 15, 124–134. [CrossRef] [PubMed]

54. Stathopoulos, P.B.; Ikura, M. Store operated calcium entry: From concept to structural mechanisms. *Cell Calcium* 2017, 63, 3–7. [CrossRef] [PubMed]

55. Ambudkar, I.S.; de Souza, L.B.; Ong, H.L. TRPC1, Orai1, and STIM1 in SOCE: Friends in tight spaces. *Cell Calcium* 2017, 63, 33–39. [CrossRef] [PubMed]

56. Glosse, P.; Feger, M.; Mutig, K.; Chen, H.; Hirche, F.; Hasan, A.A.; Gaballa, M.M.S.; Hocher, B.; Lang, F.; Foller, M. AMP-activated kinase is a regulator of fibroblast growth factor 23 production. *Kidney Int.* 2011, 79, 789–800. [CrossRef] [PubMed]

57. Hasenour, C.M.; Berglund, E.D.; Wasserman, D.H. Emerging role of AMP-activated protein kinase in endocrine control of metabolism in the liver. *Mol. Cell. Endocrinol.* 2013, 366, 152–162. [CrossRef] [PubMed]

58. Li, Y.; Xu, S.; Mihaylova, M.M.; Zheng, B.; Hou, X.; Jiang, B.; Park, O.; Luo, Z.; Lefai, E.; Shyy, J.Y.-J.; et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. *Cell Metab.* 2011, 13, 376–388. [CrossRef] [PubMed]

59. Foretz, M.; Viollet, B. Activation of AMPK for a Break in Hepatic Lipid Accumulation and Circulating Cholesterol. *EBioMedicine* 2018, 31, 15–16. [CrossRef] [PubMed]
60. Merlen, G.; Gentric, G.; Celton-Morizur, S.; Foretz, M.; Guidotti, J.-E.; Fauveau, V.; Leclerc, J.; Viollet, B.; Desdouets, C. AMPKα1 controls hepatocyte proliferation independently of energy balance by regulating Cyclin A2 expression. J. Hepatol. 2014, 60, 152–159. [CrossRef] [PubMed]

61. Foretz, M.; Viollet, B. Regulation of hepatic metabolism by AMPK. J. Hepatol. 2011, 54, 827–829. [CrossRef] [PubMed]

62. Kjøbsted, R.; Hingst, J.R.; Fentz, J.; Foretz, M.; Sanz, M.-N.; Pehmøller, C.; Shum, M.; Marette, A.; Mounier, R.; Treebak, J.T.; et al. AMPK in skeletal muscle function and metabolism. FASEB J. 2018, 32, 1741–1777. [CrossRef] [PubMed]

63. Mounier, R.; Théret, M.; Lantier, L.; Foretz, M.; Viollet, B. Expanding roles for AMPK in skeletal muscle plasticity. Trends Endocrinol. Metab. 2015, 26, 275–286. [CrossRef] [PubMed]

64. Kjøbsted, R.; Munk-Hansen, N.; Birk, J.B.; Foretz, M.; Viollet, B.; Björnholm, M.; Zierath, J.R.; Treebak, J.T.; et al. Enhanced Muscle Insulin Sensitivity After Contraction/Exercise Is Mediated by AMPK. Diabetes 2017, 66, 598–612. [CrossRef] [PubMed]

65. Cokorinos, E.C.; Delmore, J.; Reyes, A.R.; Albuquerque, B.; Kjøbsted, R.; Jørgensen, N.O.; Tran, J.-L.; Jatkar, A.; Cialdea, K.; Esquejo, R.M.; et al. Activation of Skeletal Muscle AMPK Promotes Glucose Disposal and Glucose Lowering in Non-human Primates and Mice. Cell Metab. 2017, 25, 1147–1159. [CrossRef] [PubMed]

66. Fentz, J.; Kjøbsted, R.; Birk, J.B.; Jordy, A.B.; Jeppesen, J.; Thorsen, K.; Schjerling, P.; Kiens, B.; Jessen, N.; Viollet, B.; et al. AMPKα is critical for enhancing skeletal muscle fatty acid utilization during in vivo exercise in mice. FASEB J. 2018, 32, 1725–1738. [CrossRef] [PubMed]

67. Arad, M.; Seidman, C.E.; Seidman, J.G. AMP-Activated Protein Kinase in the Heart: Role during Health and Disease. Circ. Res. 2007, 100, 474–488. [CrossRef] [PubMed]

68. Voelkl, J.; Alesutan, I.; Promessnig, U.; Feger, M.; Mia, S.; Jungmann, A.; Castor, T.; Viereck, R.; Stöckigt, F.; Borst, O.; et al. AMP-activated protein kinase α1-sensitive activation of AP-1 in cardiomyocytes. J. Mol. Cell. Cardiol. 2016, 97, 36–43. [CrossRef] [PubMed]

69. Liao, Y.; Takashima, S.; Maeda, N.; Ouchi, N.; Komamura, K.; Shimomura, I.; Hori, M.; Matsuzawa, Y.; Funahashi, T.; Kitakaze, M. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc. Res. 2005, 67, 705–713. [CrossRef] [PubMed]

70. Russell, R.R.; Li, J.; Covin, D.L.; Pypaert, M.; Zechner, C.; Palmeri, M.; Giordano, F.; Mu, J.; Birnbaum, M.J.; Young, L.H. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J. Clin. Investig. 2004, 114, 495–503. [CrossRef] [PubMed]

71. Géliñas, R.; Mailleux, F.; Donatine, J.; Bultot, L.; Demeulder, B.; Ginion, A.; Daskalopoulos, E.P.; Esfahani, H.; Dubois-Deruy, E.; Lauzier, B.; et al. AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation. Nat. Commun. 2018, 9, 374. [CrossRef] [PubMed]

72. Chen, K.; Kobayashi, S.; Xu, X.; Viollet, B.; Liang, Q. AMP activated protein kinase is indispensable for myocardial adaptation to caloric restriction in mice. PLoS ONE 2013, 8, e59682. [CrossRef] [PubMed]

73. Zhang, P.; Hu, X.; Xu, X.; Fassett, J.; Zhu, G.; Viollet, B.; Xu, W.; Wiczer, B.; Bernlohr, D.A.; Bache, R.J.; et al. AMP activated protein kinase-α2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 2008, 52, 918–924. [CrossRef] [PubMed]

74. Hallows, K.R.; Mount, P.F.; Pastor-Soler, N.M.; POWER, D.A. Role of the energy sensor AMP-activated protein kinase in renal physiology and disease. Am. J. Physiol. Renal. Physiol. 2010, 298, F1067–F1077. [CrossRef] [PubMed]

75. Pastor-Soler, N.M.; Hallows, K.R. AMP-activated protein kinase regulation of kidney tubular transport. Curr. Opin. Nephrol. Hypertens. 2012, 21, 523–533. [CrossRef] [PubMed]

76. Rajani, R.; Pastor-Soler, N.M.; Hallows, K.R. Role of AMP-activated protein kinase in kidney tubular transport, metabolism, and disease. Curr. Opin. Nephrol. Hypertens. 2017, 26, 375–383. [CrossRef] [PubMed]

77. Lee, M.-J.; Feliers, D.; Mariappan, M.M.; Sataranatarajan, K.; Mahimainathan, L.; Musi, N.; Foretz, M.; Viollet, B.; Weinberg, J.M.; Choudhury, G.G.; et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am. J. Physiol. Renal. Physiol. 2007, 292, F617–F627. [CrossRef] [PubMed]

78. Jeyabalan, J.; Shah, M.; Viollet, B.; Chenu, C. AMP-activated protein kinase pathway and bone metabolism. J. Endocrinol. 2012, 212, 277–290. [CrossRef] [PubMed]
93. Dërmaku-Sopjani, M.; Almilaji, A.; Pakladok, T.; Munoz, C.; Hosseinzadeh, Z.; Blecua, M.; Sopjani, M.; Mount, D.B. Thick ascending limb of the loop of Henle. [CrossRef] [PubMed]
94. Hallows, K.R. Emerging role of AMP-activated protein kinase in coupling membrane transport to cellular metabolism. Curr. Opin. Nephrol. Hypertens. 2005, 14, 464–471. [CrossRef] [PubMed]
95. Noske, R.; Cornelius, F.; Clarke, R.J. Investigation of the enzymatic activity of the Na\(^+\), K\(^+\)-ATPase via isothermal titration microcalorimetry. Biochim. Biophys. Acta 2010, 1797, 1540–1545. [CrossRef] [PubMed]
96. Woolhead, A.M.; Scott, J.W.; Hardie, D.G.; Baines, D.L. Phenformin and 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) activation of AMP-activated protein kinase inhibits transepithelial Na\(^+\) transport across H441 lung cells. J. Physiol. 2005, 566, 781–792. [CrossRef] [PubMed]
97. Woolhead, A.M.; Sivagnanasundaram, J.; Kalsi, K.K.; Pucovský, V.; Pellatt, L.J.; Scott, J.W.; Mustard, K.J.; Hardie, D.G.; Baines, D.L. Pharmacological activators of AMP-activated protein kinase have different effects on Na\(^+\) transport processes across human lung epithelial cells. Br. J. Pharmacol. 2007, 151, 1204–1215. [CrossRef] [PubMed]
98. Vadasz, I.; Dada, L.A.; Briva, A.; Trejo, H.E.; Welch, L.C.; Chen, J.; Tóth, P.T.; Lecuona, E.; Witters, L.A.; Schumacker, P.T.; et al. AMP-activated protein kinase regulates CO\(_2\)-induced alveolar epithelial dysfunction in rats and human cells by promoting Na, K-ATPase endocytosis. J. Clin. Investig. 2008, 118, 752–762. [CrossRef] [PubMed]
99. Gusarova, G.A.; Dada, L.A.; Kelly, A.M.; Brodie, C.; Witters, L.A.; Chandel, N.S.; Sznajder, J.I. α1-AMP-activated protein kinase regulates hypoxia-induced Na, K-ATPase endocytosis via direct phosphorylation of protein kinase C zeta. Mol. Cell. Biol. 2009, 29, 3455–3464. [CrossRef] [PubMed]
101. Benziane, B.; Björnholm, M.; Pirkmajer, S.; Austin, R.L.; Kotova, O.; Viollet, B.; Zierath, J.R.; Chibalin, A.V. Activation of AMP-activated protein kinase stimulates Na+, K+-ATPase activity in skeletal muscle cells. *J. Biol. Chem.* 2012, 287, 23451–23463. [CrossRef] [PubMed]

102. Alves, D.S.; Farr, G.A.; Seo-Mayer, P.; Caplan, M.J. AS160 associates with the Na+/K-ATPase and mediates the adenosine monophosphate-stimulated protein kinase-dependent regulation of sodium pump surface expression. *Mol. Biol. Cell* 2010, 21, 4400–4408. [CrossRef] [PubMed]

103. Seo-Mayer, P.W.; Thulin, G.; Zhang, L.; Alves, D.S.; Ardito, T.; Kashgarian, M.; Caplan, M.J. Preactivation of AMPK by metformin may ameliorate the epithelial cell damage caused by renal ischemia. *Am. J. Physiol. Renal. Physiol.* 2011, 301, F1346–F1357. [CrossRef] [PubMed]

104. Mount, P.F.; Gleich, K.; Tam, S.; Fraser, S.A.; Choy, S.-W.; Dwyer, K.M.; Lu, B.; van Denderen, B.; Fingerle-Rowson, G.; Bucala, R.; et al. The outcome of renal ischemia-reperfusion injury is unchanged in AMPK-β1 deficient mice. *PLoS ONE* 2012, 7, e29887. [CrossRef] [PubMed]

105. Fitzgerald, G.A.; Mulligan, C.; Mindell, J.A. A general method for determining secondary active transporter substrate stoichiometry. *eLife* 2017, 6. [CrossRef] [PubMed]

106. Forrest, L.R.; Krämer, R.; Ziegler, C. The structural basis of secondary active transport mechanisms. *Biochim. Biophys. Acta* 2011, 1807, 167–188. [CrossRef] [PubMed]

107. Mandel, L.J.; Balaban, R.S. Stoichiometry and coupling of active transport to oxidative metabolism in epithelial tissues. *Am. J. Physiol.* 1981, 240, F357–F371. [CrossRef] [PubMed]

108. Mather, A.; Pollock, C. Glucose handling by the kidney. *Kidney Int. Suppl.* 2011, 79, S1–S6. [CrossRef] [PubMed]

109. Bakris, G.L.; Fonseca, V.A.; Sharma, K.; Wright, E.M. Renal sodium-glucose transport: Role in diabetes mellitus and potential clinical implications. *Kidney Int.* 2009, 75, 1272–1277. [CrossRef] [PubMed]

110. Wright, E.M.; Hirayama, B.A.; Loo, D.F. Active sugar transport in health and disease. *J. Intern. Med.* 2007, 261, 32–43. [CrossRef] [PubMed]

111. Hawley, S.A.; Ford, R.J.; Smith, B.K.; Gowans, G.J.; Mancini, S.J.; Pitt, R.D.; Day, E.A.; Salt, I.P.; Steinberg, G.R.; Hardie, D.G. The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels. *Diabetes* 2016, 65, 2784–2794. [CrossRef] [PubMed]

112. You, G.; Lee, W.-S.; Barros, E.J.G.; Khawaja, S.; Wells, R.G.; Nigam, S.K.; Hediger, M.A. Molecular Characteristics of Na+-Coupled Glucose Transporters in Adult and Embryonic Rat Kidney. *J. Biol. Chem.* 1995, 270, 29365–29371. [CrossRef] [PubMed]

113. Banerjee, S.K.; Wang, D.W.; Alzamora, R.; Huang, X.N.; Pastor-Soler, N.M.; Hallows, K.R.; McGaffin, K.R.; Ahmad, F. SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in Caco-2 cells via GPR120 and AMPK. *J. Cell. Physiol.* 2018, 233, 2426–2433. [CrossRef] [PubMed]

114. Wright, E.M. Renal Na+-Glucose cotransporters. *Am. J. Physiol. Renal. Physiol.* 2001, 280, F10–F18. [CrossRef] [PubMed]

115. Pajor, A.M.; Wright, E.M. Cloning and functional expression of a mammalian Na+/nucleoside cotransporter. A member of the SGLT family. *J. Biol. Chem.* 1992, 267, 3557–3560. [PubMed]

116. Linden, K.C.; DeHaan, C.L.; Zhang, Y.; Glowacka, S.; Cox, A.J.; Kelly, D.J.; Rogers, S. Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy. *Am. J. Physiol. Renal. Physiol.* 2006, 290, F205–F213. [CrossRef] [PubMed]

117. Dominguez, J.H.; Camp, K.; Maianu, L.; Garvey, W.T. Glucose transporters of rat proximal tubule: Differential expression and subcellular distribution. *Am. J. Physiol.* 1992, 262, F807–F812. [CrossRef] [PubMed]

118. Thorens, B.; Lodish, H.F.; Brown, D. Differential localization of two glucose transporter isoforms in rat kidney. *Am. J. Physiol.* 1990, 259, C286–C294. [CrossRef] [PubMed]

119. Castilla-Madrigal, R.; Barrenetxe, J.; Moreno-Aliaga, M.J.; Lostao, M.P. E2P blocks TNF-α-induced inhibition of sugar uptake in Caco-2 cells via GPR120 and AMPK. *J. Cell. Physiol.* 2018, 233, 2426–2433. [CrossRef] [PubMed]
120. Di Franco, A.; Cantini, G.; Tani, A.; Coppini, R.; Zecchi-Orlandini, S.; Raimondi, L.; Luconi, M.; Mannucci, E. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target. *Int. J. Cardiol.* 2017, **243**, 86–90. [CrossRef] [PubMed]

121. Portilla, D. Energy metabolism and cytotoxicity. *Semin. Nephrol.* 2003, **23**, 432–438. [CrossRef]

122. Le Hir, M.; Dubach, U.C. Peroxosomal and mitochondrial β-oxidation in the rat kidney: Distribution of fatty acyl-coenzyme A oxidase and 3-hydroxyacyl-coenzyme A dehydrogenase activities along the nephron. *J. Histochem. Cytochem.* 1982, **30**, 441–444. [CrossRef] [PubMed]

123. Uchida, S.; Endou, H. Substrate specificity to maintain cellular ATP along the mouse nephron. *Am. J. Physiol.* 1988, **255**, F977–F983. [CrossRef] [PubMed]

124. Fryer, L.G.D.; Foufelle, F.; Barnes, K.; Baldwin, S.A.; Woods, A.; Carling, D. Characterization of the role of the AMP-activated protein kinase in the stimulation of glucose transport in skeletal muscle cells. *Biochem. J.* 2002, **363**, 167–174. [CrossRef] [PubMed]

125. Al-Bayati, A.; Lukka, D.; Brown, A.E.; Walker, M. Effects of thrombin on insulin signalling and glucose uptake in cultured human myotubes. *J. Diabetes Compilcat.* 2016, **30**, 1209–1216. [CrossRef] [PubMed]

126. Andrade, B.M.; Cazarin, J.; Zancan, P.; Carvalho, D.P. AMP-activated protein kinase upregulates glucose uptake in thyroid PCCL3 cells independent of thyrotropin. *Thyroid* 2012, **22**, 1063–1068. [CrossRef] [PubMed]

127. Takeno, A.; Kanazawa, I.; Notsu, M.; Tanaka, K.-I.; Sugimoto, T. Glucose uptake inhibition decreases AMP-activated protein kinase-mediated glucose transport as a novel target of tributyltin in human embryonic carcinoma cells. *Metallomics* 2013, **5**, 484–491. [CrossRef] [PubMed]

128. Wang, Y.; Zhang, Y.; Dong, M.; Wu, Z.; Shen, Z.; Xie, Y.; Kong, Z.; Dai, X.; Xu, B. Metabolic reprogramming and AMPKα1 pathway activation by caulerpin in colorectal cancer cells. *Int. J. Oncol.* 2017, **50**, 161–172. [CrossRef] [PubMed]

129. Yuzbasiyan-Gurkan, V.; Keskin, C.; Akgun, S.; Pasanin, S.; Gokce, Z.; Kose, M.; Yuzbasiyan, V.; Gul, S.; Gurkan, H.; Usta, I.; Kuzugil, I.; Andeweg, R.; Fliegel, L. Acidosis-mediated regulation of the Na\(^+\)H\(^+\) exchanger-1 (NHE1) regulation in kidney proximal tubule. *Am. J. Physiol. Renal. Physiol.* 2000, **278**, F370–F381. [CrossRef] [PubMed]

130. Odunewu, A.; Fliegel, L. Acidosis-mediated regulation of the NHE1 isoform of the Na\(^+\)/H\(^+\) exchanger in renal cells. *Am. J. Physiol. Renal. Physiol.* 2013, **305**, F370–F381. [CrossRef] [PubMed]

131. Sakar, Y.; Meddah, B.; Faouzi, M.A.; Cherrah, Y.; Bado, A.; Ducroc, R. Metformin-induced regulation of the intestinal \(\text{d-glucose transporters.} J. Physiol. Pharmacol.* 2010, **61**, 301–307. [PubMed]

132. Ogunbode, O.; Myers, E.J.; Schelling, J.R. Na\(^+\)-H\(^+\) exchanger-1 (NHE1) regulation in kidney proximal tubule. *Cell. Mol. Life Sci.* 2015, **72**, 2061–2074. [CrossRef] [PubMed]

133. Biemesderfer, D.; Reilly, R.F.; Exner, M.; Igarashi, P.; Aronson, P.S. Immunocytochemical characterization of Na\(^+\)-H\(^+\) exchanger isoform NHE1 in rabbit kidney. *Am. J. Physiol.* 1992, **263**, F833–F840. [CrossRef] [PubMed]

134. Peti-Peterdi, J.; Chambray, R.; Bebok, Z.; Biemesderfer, D.; St John, P.L.; Abrahamson, D.R.; Warnock, D.G.; Bell, P.D. Macula densa Na\(^+\)/H\(^+\) exchange activities mediated by apical NHE2 and basolateral NHE4 isoforms. *Am. J. Physiol. Renal. Physiol.* 2000, **278**, F452–F463. [CrossRef] [PubMed]

135. Baum, M.; Moe, O.W.; Gentry, D.L.; Alpern, R.J. Effect of glucocorticoids on renal cortical NHE-3 and NHE-1 mRNA. *Am. J. Physiol.* 1994, **267**, F437–F442. [CrossRef] [PubMed]
141. Hue, L.; Beauloye, C.; Marsin, A.-S.; Bertrand, L.; Hormann, S.; Rider, M.H. Insulin and Ischemia Stimulate Glycolysis by Acting on the Same Targets Through Different and Opposing Signaling Pathways. *J. Mol. Cell. Cardiol.* 2002, 34, 1091–1097. [CrossRef] [PubMed]

142. Marsin, A.-S.; Bouzir, C.; Bertrand, L.; Hue, L. The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase. *J. Biol. Chem.* 2002, 277, 30778–30783. [CrossRef] [PubMed]

143. Wyss, M.; Kaddurah-Daour, K. Creatine and creatinine metabolism. *Physiol. Rev.* 2000, 80, 1107–1213. [CrossRef] [PubMed]

144. Garcia-Delgado, M.; Peral, M.J.; Cano, M.; Calonge, M.L.; Ilundain, A.A. Creatine transport in brush-border membrane vesicles isolated from rat kidney cortex. *J. Am. Soc. Nephrol.* 2001, 12, 1819–1825. [PubMed]

145. Wallimann, T.; Wyss, M.; Brdiczka, D.; Nicolay, K.; Epenberger, H.M. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands. The ‘phosphocreatine circuit’ for cellular energy homeostasis. *Biochem. J.* 1992, 281, 21–40. [CrossRef] [PubMed]

146. Neumann, D.; Schlattner, U.; Wallimann, T. A molecular approach to the concerted action of kinases involved in energy homeostasis. *Biochem. Soc. Trans.* 2003, 31, 169–174. [CrossRef] [PubMed]

147. Li, H.; Thali, R.F.; Smolak, C.; Gong, F.; Alzamora, R.; Wallimann, T.; Scholz, R.; Pastor-Soler, N.M.; Neumann, D.; Hallows, K.R. Regulation of the creatine transporter by AMP-activated protein kinase in kidney epithelial cells. *Am. J. Physiol. Renal. Physiol.* 2010, 299, F167–F177. [CrossRef] [PubMed]

148. Darrabie, M.D.; Arciniegas, A.J.L.; Mishra, R.; Jacobs, D.O.; Santacruz, L. AMPK and substrate availability regulate creatine transport in cultured cardiomyocytes. *Am. J. Physiol. Endocrinol. Metab.* 2011, 300, E870–E876. [CrossRef] [PubMed]

149. Santacruz, L.; Arciniegas, A.J.L.; Darrabie, M.; Martilla, J.G.; Baron, R.M.; Bowles, D.E.; Mishra, R.; Jacobs, D.O. Hypoxia decreases creatine uptake in cardiomyocytes, while creatine supplementation enhances HIF activation. *Physiol. Rep.* 2017, 5. [CrossRef] [PubMed]

150. Erben, R.G.; Andrukhova, O. FGF23-Klotho signaling axis in the kidney. *Cell. Cardiol.* 2002, 300, 21–40. [CrossRef] [PubMed]

151. Hue, L.; Beauloye, C.; Marsin, A.-S.; Bertrand, L.; Horman, S.; Rider, M.H. Insulin and Ischemia Stimulate Glycolysis by Acting on the Same Targets Through Different and Opposing Signaling Pathways. *J. Mol. Cell. Cardiol.* 2002, 34, 1091–1097. [CrossRef] [PubMed]

152. Murer, H.; Forster, I.; Biber, J. The sodium phosphate cotransporter family SLC34. *Pflugers Arch.* 2009, 458, 39–52. [CrossRef] [PubMed]

153. Fraser, S.A.; Gimenez, I.; Cook, N.; Jennings, I.; Katerezos, M.; Katsis, F.; Levidiotis, V.; Kemp, B.E.; Power, D.A. Regulation of the renal-specific Na\(^{+}\)-K\(^{+}\)-2Cl\(^{-}\) co-transporter NKCC2 by AMP-activated protein kinase (AMPK). *Biochem. J.* 2007, 405, 85–93. [CrossRef] [PubMed]

154. Cook, N.; Fraser, S.A.; Katerelos, M.; Katsis, F.; Gleich, K.; Mount, P.F.; Steinberg, G.R.; Levidiotis, V.; Kemp, B.E.; Power, D.A. Low salt concentrations activate AMP-activated protein kinase in mouse macula densa cells. *Am. J. Physiol. Renal. Physiol.* 2009, 296, F801–F809. [CrossRef] [PubMed]

155. Fraser, S.A.; Choy, S.-W.; Pastor-Soler, N.M.; Li, H.; Davies, M.R.P.; Cook, N.; Katerelos, M.; Mount, P.F.; Gleich, K.; McRae, J.L.; et al. AMPK couples plasma renin to cellular metabolism by phosphorylation of ACC1. *Am. J. Physiol. Renal. Physiol.* 2013, 305, F679–F690. [CrossRef] [PubMed]

156. Efe, O.; Klein, J.D.; LaRocque, L.M.; Ren, H.; Sanders, J.M. Metformin improves urine concentration in rodents with nephrogenic diabetes insipidus. *JCI Insight* 2016, 1. [CrossRef] [PubMed]

157. Udwan, K.; Abed, A.; Roth, I.; Dizin, E.; Maillard, M.; Bettoni, C.; Loffing, J.; Wagner, C.A.; Edwards, A.; Feraille, E. Dietary sodium induces a redistribution of the tubular metabolic workload. *J. Physiol.* 2017, 595, 6905–6922. [CrossRef] [PubMed]

158. Siraskar, B.; Huang, D.Y.; Pakladok, T.; Siraskar, G.; Sopjani, M.; Alesutan, I.; Kucherenko, Y.; Almilaji, A.; Devanathan, V.; Shumilina, E.; et al. Downregulation of the renal outer medullary K\(^{+}\) channel ROMK by the AMP-activated protein kinase. *Pflugers Arch.* 2013, 465, 233–245. [CrossRef] [PubMed]

159. Hallows, K.R.; Raghuram, V.; Kemp, B.E.; Witters, L.A.; Foskett, J.K. Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase. *J. Clin. Investig.* 2000, 105, 1711–1721. [CrossRef] [PubMed]

160. Morales, M.M.; Falkenstein, D.; Lopes, A.G. The Cystic Fibrosis Transmembrane Regulator (CFTR) in the kidney. *An. Acad. Bras. Ciênc.* 2000, 72, 399–406. [CrossRef] [PubMed]
161. Hallows, K.R.; McCane, J.E.; Kemp, B.E.; Witters, L.A.; Foskett, J.K. Regulation of channel gating by AMP-activated protein kinase modulates cystic fibrosis transmembrane conductance regulator activity in lung submucosal cells. *J. Biol. Chem.* 2003, 278, 998–1004. [CrossRef] [PubMed]

162. King, J.D.; Fitch, A.C.; Lee, J.K.; McCane, J.E.; Mak, D.-O.D.; Foskett, J.K.; Hallows, K.R. AMP-activated protein kinase phosphorylation of the R domain inhibits PKA stimulation of CFTR. *Am. J. Physiol. Cell Physiol.* 2009, 297, C94–C101. [CrossRef] [PubMed]

163. Kongsuphol, P.; Hieke, B.; Ousingsawat, J.; Almaca, J.; Viollet, B.; Schreiber, R.; Kunzelmann, K. Regulation of Cl− secretion by AMPK in vivo. *Pflugers Arch.* 2009, 457, 1071–1078. [CrossRef] [PubMed]

164. Li, H.; Findlay, I.A.; Sheppard, S.V.; Kittayaruksakul, S.; Homvisasevongsa, S.; Somlo, S.; Chatsudhipong, V. Steviol retards renal cyst growth through reduction of CFTR expression and inhibition of epithelial cell proliferation in a mouse model of polycystic kidney disease. *Biochem. Pharmacol.* 2014, 88, 412–421. [CrossRef] [PubMed]

165. Takiar, V.; Nishio, S.; Seo-Mayer, P.; King, J.D.; Li, H.; Zhang, L.; Karihaloo, A.; Hallows, K.R.; Somlo, S.; Caplan, M.J. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. *Proc. Natl. Acad. Sci. USA* 2011, 108, 2462–2467. [CrossRef] [PubMed]

166. Yuajit, C.; Muanprasat, C.; Gallagher, A.-R.; Fedele, S.V.; Kittayaruksakul, S.; Homvisasevongsa, S.; Somlo, S.; Chatsudhipong, V. AMPK controls epithelial Na+ channel for the fine-tuning of Ca2+ reabsorption. *Handb. Exp. Pharmacol.* 2014, 222, 321–357. [PubMed]

167. Jeon, U.S. Kidney and calcium homeostasis. *Electrolyte Blood Press.* 2008, 6, 68–76. [CrossRef] [PubMed]

168. Na, T.; Peng, J.-B. TRPV5: A Ca2+ channel for the fine-tuning of Ca2+ reabsorption. *Am. J. Physiol. Renal. Physiol.* 2001, 280, F1093–F1106. [CrossRef] [PubMed]

169. Nurbaeva, M.K.; Schmid, E.; Szteyn, K.; Yang, W.; Viollet, B.; Shumilina, E.; Lang, F. Enhanced Ca2+ entry and Na+/Ca2+ exchanger activity in dendritic cells from AMP-activated protein kinase-deficient mice. *FASEB J.* 2012, 26, 3049–3058. [CrossRef] [PubMed]

170. Lang, F.; Föller, M. Regulation of ion channels and transporters by AMP-activated kinase (AMPK). *Channels (Austin)* 2014, 8, 20–28. [CrossRef] [PubMed]

171. Bhavsar, S.K.; Schmidt, S.; Bobbala, D.; Nurbaeva, M.K.; Hosseinzadeh, Z.; Merches, K.; Fajol, A.; Wilmes, J.; Lang, F. AMPKα1-sensitivity of Orai1 and Ca2+ entry in T-lymphocytes. *Cell. Physiol. Biochem.* 2013, 32, 687–698. [CrossRef] [PubMed]

172. Mai, X.; Shang, J.; Liang, S.; Yu, B.; Yuan, J.; Lin, Y.; Luo, R.; Zhang, F.; Liu, Y.; Lv, X.; et al. Blockade of Orai1 Store-Operated Calcium Entry Protects against Renal Fibrosis. *J. Am. Soc. Nephrol.* 2016, 27, 3063–3078. [CrossRef] [PubMed]

173. Zaika, O.; Mamenko, M.; Starschenko, A.; Pochynyuk, O. Direct activation of ENaC by angiotensin II: Recent advances and new insights. *Curr. Hypertens. Rep.* 2013, 15, 17–24. [CrossRef] [PubMed]

174. Shigaev, A.; Asher, C.; Latter, H.; Garty, H.; Reuveny, E. Regulation of sgk by aldosterone and its effects on the epithelial Na+ channel. *Am. J. Physiol. Renal. Physiol.* 2000, 278, F613–F619. [CrossRef] [PubMed]

175. Staruschenko, A.; Kunzelmann, K. Regulation of transport in the connecting tubule and cortical collecting duct. *Compr. Physiol.* 2012, 2, 1541–1584. [PubMed]

176. Bhalla, V.; Hallows, K.R. Mechanisms of ENaC regulation and clinical implications. *J. Am. Soc. Nephrol.* 2008, 19, 1845–1854. [CrossRef] [PubMed]

177. Bhalla, V.; Oyster, N.M.; Fitch, A.C.; Wijngaarden, M.A.; Neumann, D.; Schlattner, U.; Pearce, D.; Hallows, K.R. AMP-activated kinase inhibits the epithelial Na+ channel through functional regulation of the ubiquitin ligase Nedd4-2. *J. Biol. Chem.* 2006, 281, 26159–26169. [CrossRef] [PubMed]

178. Hager, H.; Kwon, T.H.; Vinnikova, A.K.; Masilamani, S.; Brooks, H.L.; Frekiaer, J.; Knepper, M.A.; Nielsen, S. Immunocytochemical and immunoelectron microscopic localization of α-, β-, and γ-ENaC in rat kidney. *Am. J. Physiol. Renal. Physiol.* 2001, 280, F1093–F1106. [CrossRef] [PubMed]

179. Myerburg, M.M.; King, J.D.; Oyster, N.M.; Fitch, A.C.; Magill, A.; Baty, C.J.; Watkins, S.C.; Kolls, J.K.; Pilewski, J.M.; Hallows, K.R. AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells. *Am. J. Respir. Cell Mol. Biol.* 2010, 42, 676–684. [CrossRef] [PubMed]

180. Almaça, J.; Kongsuphol, P.; Hieke, B.; Ousingsawat, J.; Viollet, B.; Schreiber, R.; Amaral, M.D.; Kunzelmann, K. AMPK controls epithelial Na+ channels through Nedd4-2 and causes an epithelial phenotype when mutated. *Pflugers Arch.* 2009, 458, 713–721. [CrossRef] [PubMed]
181. Carattino, M.D.; Edinger, R.S.; Grieser, H.J.; Wise, R.; Neumann, D.; Schlattner, U.; Johnson, J.P.; Kleyman, T.R.; Hallows, K.R. Epithelial sodium channel inhibition by AMP-activated protein kinase in oocytes and polarized renal epithelial cells. *J. Biol. Chem.* 2005, 280, 17608–17616. [CrossRef] [PubMed]

182. Yu, H.; Yang, T.; Gao, P.; Wei, X.; Zhang, H.; Xiong, S.; Lu, Z.; Li, L.; Wei, X.; Chen, J.; et al. Caffeine intake antagonizes salt sensitive hypertension through improvement of renal sodium handling. *Sci. Rep.* 2016, 6, 25746. [CrossRef] [PubMed]

183. Weixel, K.M.; Marciszyn, A.; Alzamora, R.; Li, H.; Fischer, O.; Edinger, R.S.; Hallows, K.R.; Johnson, J.P. Resveratrol inhibits the epithelial sodium channel via phosphoinositides and AMP-activated protein kinase in kidney collecting duct cells. *PLoS ONE* 2013, 8, e78019. [CrossRef] [PubMed]

184. Ho, P.-Y.; Li, H.; Pavlov, T.S.; Tuerk, R.D.; Tabares, D.; Brunisholz, R.; Neumann, D.; Staruschenko, A.; Hallows, K.R. β1Pix exchange factor stabilizes the ubiquitin ligase Nedd4-2 and plays a critical role in ENaC regulation by AMPK in kidney epithelial cells. *J. Biol. Chem.* 2018, 293, 11612–11624. [CrossRef] [PubMed]

185. Huang, D.Y.; Gao, H.; Boini, K.M.; Osswald, H.; Nürnberg, B.; Lang, F. In vivo stimulation of AMP-activated protein kinase enhanced tubuloglomerular feedback but reduced tubular sodium transport during high dietary NaCl intake. *Pflugers Arch.* 2010, 460, 187–196. [CrossRef] [PubMed]

186. Lazo-Fernández, Y.; Baile, G.; Meade, P.; Torcal, P.; Martinez, L.; Ibañez, C.; Bernal, M.L.; Viollet, B.; Giménez, I. Kidney-specific genetic deletion of both AMPK α-subunits causes salt and water wasting. *Am J. Physiol. Renal. Physiol.* 2017, 312, F352–F365. [CrossRef] [PubMed]

187. Alzamora, R.; Gong, F.; Rondanino, C.; Lee, J.K.; Smolak, C.; Pastor-Soler, N.M.; Hallows, K.R. AMP-activated protein kinase inhibits KCNQ1 channels through regulation of the ubiquitin ligase Nedd4-2 in renal epithelial cells. *Am. J. Physiol. Renal. Physiol.* 2010, 299, F1308–F1319. [CrossRef] [PubMed]

188. Vallon, V.; Grahhammer, F.; Richter, K.; Bleich, M.; Lang, F.; Barhanin, J.; Völkl, H.; Warth, R. Role of KCN1-dependent K⁺ fluxes in mouse proximal tubule. *J. Am. Soc. Nephrol.* 2001, 12, 2003–2011. [PubMed]

189. Vallon, V.; Grahhammer, F.; Völkl, H.; Sandu, C.D.; Richter, K.; Rexhepaj, R.; Gerlach, U.; Rong, Q.; Péfier, K.; Lang, F. KCNQ1-dependent transport in renal and gastrointestinal epithelia. *Proc. Natl. Acad. Sci. USA* 2005, 102, 17864–17869. [CrossRef] [PubMed]

190. Andersen, M.N.; Krzystanek, K.; Jespersen, T.; Olesen, S.-P.; Rasmussen, H.B. AMP-activated protein kinase downregulates Kv7.1 cell surface expression. *Traffic* 2012, 13, 143–156. [CrossRef] [PubMed]

191. Alesutan, H.; Föller, M.; Sopjani, M.; Dërmaku-Sopjani, M.; Zelenak, C.; Fröhlich, H.; Velic, A.; Fraser, S.; Andersen, M.N.; Krzystanek, K.; Jespersen, T.; Olesen, S.-P.; Rasmussen, H.B. AMP-activated protein kinase inhibits ATPase apical accumulation in kidney intercalated cells is regulated by PKA and AMP-activated protein kinase. *J. Biol. Chem.* 2010, 285, F1162–F1169. [CrossRef] [PubMed]

192. Al-Bataineh, M.M.; Gong, F.; Smolak, C.; Neumann, D.; Pastor-Soler, N.M.; Hallows, K.R. AMP-activated protein kinase inhibits alkaline pH- and PKA-induced apical vacuolar H⁺-ATPase accumulation in kidney cells. *J. Biol. Chem.* 2009, 284, C672–C681. [CrossRef] [PubMed]

193. Alzamora, R.; Al-Bataineh, M.M.; Liu, W.; Gong, F.; Li, H.; Thali, R.F.; Joho-Auchli, Y.; Brunisholz, R.A.; Satlin, L.M.; Neumann, D.; et al. AMP-activated protein kinase regulates the vacuolar H⁺-ATPase via direct phosphorylation of the A subunit (ATP6V1A) in the kidney. *Am. J. Physiol. Renal. Physiol.* 2013, 305, F943–F956. [CrossRef] [PubMed]

194. Al-Bataineh, M.M.; Gong, F.; Smolak, C.; Li, H.; Baty, C.J.; Bertrand, C.A.; Auchli, Y.; Brunisholz, R.A.; Neumann, D.; et al. PKA regulates vacuolar H⁺-ATPase localization and activity via direct phosphorylation of the α subunit in kidney cells. *J. Biol. Chem.* 2010, 285, 24676–24685. [CrossRef] [PubMed]

195. McGuire, C.M.; Forgac, M. Glucose starvation increases V-ATPase assembly and activity in mammalian cells through AMP kinase and phosphatidylinositide 3-kinase/Akt signaling. *J. Biol. Chem.* 2018, 293, 9113–9123. [CrossRef] [PubMed]

196. Collins, M.P.; Forgac, M. Regulation of V-ATPase Assembly in Nutrient Sensing and Function of V-ATPases in Breast Cancer Metastasis. *Front. Physiol.* 2018, 9, 902. [CrossRef] [PubMed]
199. Sands, J.M.; Klein, J.D. Physiological insights into novel therapies for nephrogenic diabetes insipidus. *Am. J. Physiol. Renal. Physiol.* 2016, 311, F1149–F1152. [CrossRef] [PubMed]

200. Denton, J.S.; Pao, A.C.; Maduke, M. Novel diuretic targets. *Am. J. Physiol. Renal. Physiol.* 2013, 305, F931–F942. [CrossRef] [PubMed]

201. Bech, A.P.; Wetzels, J.F.M.; Nijenhuis, T. Effects of sildenafil, metformin, and simvastatin on ADH-independent urine concentration in healthy volunteers. *Physiol. Rep.* 2018, 6, e13665. [CrossRef] [PubMed]

202. Klein, J.D.; Wang, Y.; Blount, M.A.; Molina, P.A.; LaRocque, L.M.; Ruiz, J.A.; Sands, J.M. Metformin, an AMPK activator, stimulates the phosphorylation of aquaporin 2 and urea transporter A1 in inner medullary collecting ducts. *Am. J. Physiol. Renal. Physiol.* 2016, 310, F1008–F1012. [CrossRef] [PubMed]

203. Al-bataineh, M.M.; Li, H.; Ohmi, K.; Gong, F.; Marciszyn, A.L.; Naveed, S.; Zhu, X.; Neumann, D.; Wu, Q.; Cheng, L.; et al. Activation of the metabolic sensor AMP-activated protein kinase inhibits aquaporin-2 function in kidney principal cells. *Am. J. Physiol. Renal. Physiol.* 2016, 311, F890–F900. [CrossRef] [PubMed]

204. Andersen, M.N.; Rasmussen, H.B. AMPK: A regulator of ion channels. *Commun. Integr. Biol.* 2012, 5, 480–484. [CrossRef] [PubMed]

205. Nickolas, T.L.; Jamal, S.A. Bone kidney interactions. *Rev. Endocr. Metab. Disord.* 2015, 16, 157–163. [CrossRef] [PubMed]

206. Graciolli, F.G.; Neves, K.R.; Barreto, F.; Barreto, D.V.; Dos Reis, L.M.; Canziani, M.E.; Sabbagh, Y.; Carvalho, A.B.; Jorgetti, V.; Elias, R.M.; et al. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease. *Kidney Int.* 2017, 91, 1436–1446. [CrossRef] [PubMed]

207. Alesutan, I.; Munoz, C.; Sopjani, M.; Dërmaku-Sopjani, M.; Michael, D.; Fraser, S.; Kemp, B.E.; Seeboldm, G.; Föller, M.; Lang, F. Inhibition of Kir2.1 (KCNJ2) by the AMP-activated protein kinase. *Biochem. Biophys. Res. Commun.* 2011, 408, 505–510. [CrossRef] [PubMed]

208. Derst, C.; Karschin, C.; Wischmeyer, E.; Hirsch, J.R.; Preisig-Müller, R.; Rajan, S.; Engel, H.; Grzeschik, K.-H.; Daut, J.; Karschin, A. Genetic and functional linkage of Kir5.1 and Kir2.1 channel subunits. *FEBS Lett.* 2001, 491, 305–311. [CrossRef] [PubMed]

209. Mia, S.; Munoz, C.; Pakladok, T.; Siraskar, G.; Voelkl, J.; Alesutan, I.; Lang, F. Downregulation of Kv1.5 K channels by the AMP-activated protein kinase. *Cell. Physiol. Biochem.* 2012, 30, 1039–1050. [CrossRef] [PubMed]

210. Bielanska, J.; Hernandez-Losa, J.; Perez-Verdaguer, M.; Moline, T.; Somoza, R.; Cail, S.; Condom, E.; Ferreres, J.; Felipe, A. Voltage-Dependent Potassium Channels Kv1.3 and Kv1.5 in Human Cancer. *Curr. Cancer Drug Targets* 2009, 9, 904–914. [CrossRef] [PubMed]

211. Almilaji, A.; Munoz, C.; Elvira, B.; Fajol, A.; Pakladok, T.; Honisch, S.; Shumilina, E.; Lang, F.; Föller, M. AMP-activated protein kinase regulates hERG potassium channel. *Pflugers Arch.* 2013, 465, 1573–1582. [CrossRef] [PubMed]

212. Wadhwa, S.; Wadhwa, P.; Dinda, A.K.; Gupta, N.P. Differential expression of potassium ion channels in human renal cell carcinoma. *Int. Urol. Nephrol.* 2009, 41, 251–257. [CrossRef] [PubMed]

213. Munoz, C.; Sopjani, M.; Dërmaku-Sopjani, M.; Almilaji, A.; Föller, M.; Lang, F. Downregulation of the osmolyte transporters SMIT and BGT1 by AMP-activated protein kinase. *Biochem. Biophys. Res. Commun.* 2012, 422, 358–362. [CrossRef] [PubMed]

214. Yamauchi, A.; Nakanishi, T.; Takamitsu, Y.; Sugita, M.; Imai, E.; Noguchi, T.; Fujiwara, Y.; Kamada, T.; Ueda, N. In vivo osmoregulation of Na/myo-inositol cotransporter mRNA in rat kidney medulla. *J. Am. Soc. Nephrol.* 1994, 5, 62–67. [CrossRef] [PubMed]

215. Rasola, A.; Galietta, L.J.; Barone, V.; Romeo, G.; Bagnasco, S. Molecular cloning and functional characterization of a GABA/betaine transporter from human kidney. *FEBS Lett.* 1995, 373, 229–233. [CrossRef]

216. Zhou, Y.; Holmseth, S.; Hua, R.; Lehre, A.C.; Olofsson, A.M.; Poblete-Naredo, I.; Kempson, S.A.; Danbolt, N.C. The betaine-GABA transporter (BGT1, slc6a12) is predominantly expressed in the liver and at lower levels in the kidneys and at the brain surface. *Am. J. Physiol. Renal. Physiol.* 2012, 302, F316–F328. [CrossRef] [PubMed]

217. Sopjani, M.; Alesutan, I.; Dërmaku-Sopjani, M.; Fraser, S.; Kemp, B.E.; Föller, M.; Lang, F. Down-regulation of Na+ -coupled glutamate transporter EAAT3 and EAAT4 by AMP-activated protein kinase. *J. Neurochem.* 2010, 113, 1426–1435. [CrossRef] [PubMed]
218. Hu, Q.X.; Ottestad-Hansen, S.; Holmseth, S.; Hassel, B.; Danbolt, N.C.; Zhou, Y. Expression of Glutamate Transporters in Mouse Liver, Kidney, and Intestine. *J. Histochem. Cytochem.* 2018, 66, 189–202. [CrossRef] [PubMed]

219. Schmitt, R.; Ellison, D.H.; Farman, N.; Rossier, B.C.; Reilly, R.F.; Reeves, W.B.; Oberbäumer, I.; Tapp, R.; Bachmann, S. Developmental expression of sodium entry pathways in rat nephron. *Am. J. Physiol. Renal. Physiol.* 1999, 276, F367–F381. [CrossRef]

220. Kórnéisz, O.; Benoit, J.P.; Bayliss, D.A.; Mulkey, D.K. AMP-activated protein kinase inhibits TREK channels. *J. Physiol.* 2009, 587, 5819–5830. [CrossRef] [PubMed]

221. Gu, W.; Schlichthörl, G.; Hirsch, J.R.; Engels, H.; Karschin, C.; Karschin, A.; Derst, C.; Steinlein, O.K.; Daut, J. Expression pattern and functional characteristics of two novel splice variants of the two-pore-domain potassium channel TREK-2. *J. Physiol.* 2002, 539, 657–668. [CrossRef] [PubMed]

222. Föller, M.; Jaumann, M.; Dettling, J.; Saxena, A.; Pakladok, T.; Munoz, C.; Ruth, P.; Sopjani, M.; Seebohm, G.; Rüttiger, L.; et al. AMP-activated protein kinase in BK-channel regulation and protection against hearing loss following acoustic overstimulation. *FASEB J.* 2012, 26, 4243–4253. [CrossRef] [PubMed]

223. Rabjerg, M.; Oliván-Viguera, A.; Hansen, L.K.; Jensen, L.; Sevelsted-Møller, L.; Walter, S.; Jensen, B.L.; Marcusen, N.; Köhler, R. High expression of KCa3.1 in patients with clear cell renal carcinoma predicts high metastatic risk and poor survival. *PLoS ONE* 2015, 10, e0122992. [CrossRef] [PubMed]

224. Wyatt, C.N.; Mustard, K.J.; Pearson, S.A.; Dallas, M.L.; Atkinson, L.; Kumar, P.; Peers, C.; Hardie, D.G.; Evans, A.M. AMP-activated protein kinase mediates carotid body excitation by hypoxia. *J. Biol. Chem.* 2007, 282, 8092–8098. [CrossRef] [PubMed]

225. Yoshida, H.; Bao, L.; Kefaloyianni, E.; Taskin, E.; Okorie, U.; Hong, M.; Bao, L.; Kefaloyianni, E.; Taskin, E.; Okorie, U.; Hong, M.; Dhar-Chowdhury, P.; Kaneko, M.; Coetzee, W.A. AMP-activated protein kinase connects cellular energy metabolism to KATP channel function. *J. Mol. Cell. Cardiol.* 2012, 52, 410–418. [CrossRef] [PubMed]

226. Lim, A.; Park, S.-H.; Sohn, J.-W.; Jeon, J.-H.; Park, J.-H.; Song, D.-K.; Lee, S.-H.; Ho, W.-K. Glucose deprivation regulates KATP channel trafficking via AMP-activated protein kinase in pancreatic β-cells. *Diabetes* 2009, 58, 2813–2819. [CrossRef] [PubMed]

227. Chang, T.-J.; Chen, W.-P.; Yang, C.; Lu, P.-H.; Liang, Y.-C.; Su, M.-J.; Lee, S.-C.; Chuang, L.-M. Serine-385 phosphorylation of inwardly rectifying K+ channel subunit (Kir6.2) by AMP-dependent protein kinase plays a key role in rosiglitazone-induced closure of the K(ATP) channel and insulin secretion in rats. *Diabetologia* 2009, 52, 1112–1121. [CrossRef] [PubMed]

228. Tan, X.-H.; Zheng, X.-M.; Yu, L.-X.; He, J.; Zhu, H.-M.; Ge, X.-P.; Ren, X.-L.; Ye, F.-Q.; Bellusci, S.; Xiao, J.; et al. Fibroblast growth factor 2 protects against renal ischaemia/reperfusion injury by attenuating mitochondrial damage and proinflammatory signalling. *J. Cell. Mol. Med.* 2017, 21, 2909–2925. [CrossRef] [PubMed]

229. Klein, H.; Garneau, L.; Trinh, N.T.N.; Privé, A.; Dionne, F.; Goupil, E.; Thuringer, D.; Parent, L.; Brochiero, E.; Sauvé, R. Inhibition of the KCa3.1 channels by AMP-activated protein kinase in human airway epithelial cells. *Am. J. Physiol. Cell Physiol.* 2009, 296, C285–C295. [CrossRef] [PubMed]

230. Huang, C.; Shen, S.; Ma, Q.; Chen, J.; Gill, A.; Pollock, C.A.; Chen, X.-M. Blockade of KCa3.1 ameliorates renal fibrosis through the TGF-β1/Smad pathway in diabetic mice. *Diabetes* 2013, 62, 2923–2934. [CrossRef] [PubMed]

231. Takimoto, M.; Takeyama, M.; Hamada, T. Possible involvement of AMPK in acute exercise-induced expression of monocarboxylate transporters MCT1 and MCT4 mRNA in fast-twitch skeletal muscle. *Metab. Clin. Exp.* 2013, 62, 1633–1640. [CrossRef] [PubMed]

232. Becker, H.M.; Mohebbi, N.; Perna, A.; Ganapathy, V.; Capasso, G.; Wagner, C.A. Localization of members of MCT monocarboxylate transporter family Slc16 in the kidney and regulation during metabolic acidosis. *Am. J. Physiol. Renal. Physiol.* 2010, 299, F141–F154. [CrossRef] [PubMed]

233. Fisel, P.; Kruck, S.; Winter, S.; Bedke, J.; Hennenlotter, J.; Nies, A.T.; Scharpf, M.; Fend, F.; Stenzl, A.; Schwab, M.; et al. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome. *Clin. Cancer Res.* 2013, 19, 5170–5181. [CrossRef] [PubMed]

234. Pieri, M.; Christian, H.C.; Wilkins, R.J.; Boyd, C.A.R.; Meredith, D. The apical (hPepT1) and basolateral peptide transport systems of Caco-2 cells are regulated by AMP-activated protein kinase. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2010, 299, G136–G143. [CrossRef] [PubMed]
235. Shen, H.; Smith, D.E.; Yang, T.; Huang, Y.G.; Schnermann, J.B.; Brosius, F.C. Localization of PEPT1 and PEPT2 proton-coupled oligopeptide transporter mRNA and protein in rat kidney. *Am. J. Physiol. Renal. Physiol.* **1999**, *276*, F658–F665. [CrossRef]

236. Shen, B.; Zhu, J.; Zhang, J.; Jiang, F.; Wang, Z.; Zhang, Y.; Li, J.; Huang, D.; Ke, D.; Ma, R.; et al. Attenuated mesangial cell proliferation related to store-operated Ca\(^{2+}\) entry in aged rat: The role of STIM 1 and Orai 1. *Age* **2013**, *35*, 2193–2202. [CrossRef] [PubMed]